Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • Clinical Oncology
      • Immuno-oncology
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov October 1 2019 9 (10) 1325-1328; DOI:10.1158/2159-8290.CD-ITI9-10

In the Spotlight

  • In the Spotlight
    Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
    Jose M. Pacheco and Lauren Averett Byers
    Cancer Discov October 1 2019 9 (10) 1340-1342; DOI:10.1158/2159-8290.CD-19-0850

  • In the Spotlight
    Single-Cell RNA Sequencing Reveals a Developmental Hierarchy in Langerhans Cell Histiocytosis
    Tanja A. Gruber
    Cancer Discov October 1 2019 9 (10) 1343-1345; DOI:10.1158/2159-8290.CD-19-0820

  • In the Spotlight
    Bringing Oncohistones into the Fold
    Jay F. Sarthy and Steven Henikoff
    Cancer Discov October 1 2019 9 (10) 1346-1348; DOI:10.1158/2159-8290.CD-19-0839

Mini Review

  • Mini Review
    Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
    Lynda Vuong, Ritesh R. Kotecha, Martin H. Voss and A. Ari Hakimi
    Cancer Discov October 1 2019 9 (10) 1349-1357; DOI:10.1158/2159-8290.CD-19-0499

Research Brief

  • Research Brief
    Distinct Colorectal Cancer–Associated APC Mutations Dictate Response to Tankyrase Inhibition
    Emma M. Schatoff, Sukanya Goswami, Maria Paz Zafra, Miguel Foronda, Michael Shusterman, Benjamin I. Leach, Alyna Katti, Bianca J. Diaz and Lukas E. Dow
    Cancer Discov October 1 2019 9 (10) 1358-1371; DOI:10.1158/2159-8290.CD-19-0289

    The locations of mutations in APC, which hyperactivate WNT signaling and are common in colorectal cancers, dictate whether tankyrase inhibition can restore normal WNT signaling.

Research Articles

  • Research Articles | AuthorChoice
    Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
    Anna F. Farago, Beow Y. Yeap, Marcello Stanzione, Yin P. Hung, Rebecca S. Heist, J. Paul Marcoux, Jun Zhong, Deepa Rangachari, David A. Barbie, Sarah Phat, David T. Myers, Robert Morris, Marina Kem, Taronish D. Dubash, Elizabeth A. Kennedy, Subba R. Digumarthy, Lecia V. Sequist, Aaron N. Hata, Shyamala Maheswaran, Daniel A. Haber, Michael S. Lawrence, Alice T. Shaw, Mari Mino-Kenudson, Nicholas J. Dyson and Benjamin J. Drapkin
    Cancer Discov October 1 2019 9 (10) 1372-1387; DOI:10.1158/2159-8290.CD-19-0582

    A phase I/II clinical trial of the PARP inhibitor olaparib with the DNA-alkylating agent temozolomide in small-cell lung cancer provided preliminary evidence of efficacy, and a co-clinical trial using patient-derived xenografts revealed possible biomarkers for response.

  • Research Articles | AuthorChoice
    Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
    Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G.S. Mortimer, Justin I. Odegaard, Elizabeth A. Harrington, Juyoung Lee, Taehyang Lee, Sung Yong Oh, Jung-Hun Kang, Jung Hoon Kim, Youjin Kim, Jun Ho Ji, Young Saing Kim, Kyoung Eun Lee, Jinchul Kim, Tae Sung Sohn, Ji Yeong An, Min-Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Jae J. Kim, Yang Won Min, Byung-Hoon Min, Nayoung K.D. Kim, Sally Luke, Young Hwa Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung-Mee Kim and Won Ki Kang
    Cancer Discov October 1 2019 9 (10) 1388-1405; DOI:10.1158/2159-8290.CD-19-0442

    Biomarker-based treatment of patients with gastric cancer was associated with an improved overall response rate, and patients with MET amplifications who received savolitinib exhibited especially promising responses.

  • Research Articles | AuthorChoice
    Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis
    Florian Halbritter, Matthias Farlik, Raphaela Schwentner, Gunhild Jug, Nikolaus Fortelny, Thomas Schnöller, Hanja Pisa, Linda C. Schuster, Andrea Reinprecht, Thomas Czech, Johannes Gojo, Wolfgang Holter, Milen Minkov, Wolfgang M. Bauer, Ingrid Simonitsch-Klupp, Christoph Bock and Caroline Hutter
    Cancer Discov October 1 2019 9 (10) 1406-1421; DOI:10.1158/2159-8290.CD-19-0138

    Single-cell analysis of Langerhans cell histiocytosis lesions revealed cellular and molecular heterogeneity suggestive of a developmental hierarchy shared among lesions.

  • Research Articles
    The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
    Wenjuan Dong, Xiaojin Wu, Shoubao Ma, Yufeng Wang, Ansel P. Nalin, Zheng Zhu, Jianying Zhang, Don M. Benson, Kai He, Michael A. Caligiuri and Jianhua Yu
    Cancer Discov October 1 2019 9 (10) 1422-1437; DOI:10.1158/2159-8290.CD-18-1259

    The counterintuitive response of some PD-L1- tumors to anti–PD-L1 therapy may be a result of PD-L1 expression on natural killer (NK) cells, which can be triggered by contact between NK cells and myeloid leukemia cells.

  • Research Articles
    A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
    Richard L. Bennett, Aditya Bele, Eliza C. Small, Christine M. Will, Behnam Nabet, Jon A. Oyer, Xiaoxiao Huang, Rajarshi P. Ghosh, Adrian T. Grzybowski, Tao Yu, Qiao Zhang, Alberto Riva, Tanmay P. Lele, George C. Schatz, Neil L. Kelleher, Alexander J. Ruthenburg, Jan Liphardt and Jonathan D. Licht
    Cancer Discov October 1 2019 9 (10) 1438-1451; DOI:10.1158/2159-8290.CD-19-0393

    Mutations in the bodies of core histone proteins recur in cancers; the most common one (H2BE76K) destabilizes nucleosomes, increases chromatin accessibility, alters gene expression, and increases proliferation of normal epithelial cells.

  • Research Articles | AuthorChoice
    Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis
    Justin Taylor, Maria Sendino, Alexander N. Gorelick, Alessandro Pastore, Matthew T. Chang, Alexander V. Penson, Elena I. Gavrila, Connor Stewart, Ella M. Melnik, Florisela Herrejon Chavez, Lillian Bitner, Akihide Yoshimi, Stanley Chun-Wei Lee, Daichi Inoue, Bo Liu, Xiao J. Zhang, Anthony R. Mato, Ahmet Dogan, Michael G. Kharas, Yuhong Chen, Demin Wang, Rajesh K. Soni, Ronald C. Hendrickson, Gorka Prieto, Jose A. Rodriguez, Barry S. Taylor and Omar Abdel-Wahab
    Cancer Discov October 1 2019 9 (10) 1452-1467; DOI:10.1158/2159-8290.CD-19-0298

    Recurrent and lineage-specific mutations in the nuclear-export receptor XPO1 alter the distribution of proteins in the nucleus and cytoplasm and promote oncogenesis in vitro and in vivo.

News in Brief

  • News in Brief
    People
    Cancer Discov October 1 2019 9 (10) 1330-1330; DOI:10.1158/2159-8290.CD-NB2019-095

  • News in Brief
    Immunotherapy Shows Promise in Pancreatic Cancer
    Cancer Discov October 1 2019 9 (10) 1330-1330; DOI:10.1158/2159-8290.CD-NB2019-096

  • News in Brief
    Gone Wildling: Building a Better Lab Mouse
    Cancer Discov October 1 2019 9 (10) 1331-1331; DOI:10.1158/2159-8290.CD-NB2019-100

  • News in Brief
    Exact Sciences Buys Genomic Health for $2.8 Billion
    Cancer Discov October 1 2019 9 (10) 1331-1332; DOI:10.1158/2159-8290.CD-NB2019-099

  • News in Brief
    Fedratinib Becomes New Option in Myelofibrosis
    Cancer Discov October 1 2019 9 (10) 1332-1332; DOI:10.1158/2159-8290.CD-NB2019-102

  • News in Brief
    Sylvester Cancer Center Receives NCI Designation
    Cancer Discov October 1 2019 9 (10) 1332-1333; DOI:10.1158/2159-8290.CD-NB2019-098

  • News in Brief
    Noted
    Cancer Discov October 1 2019 9 (10) 1333-1333; DOI:10.1158/2159-8290.CD-NB2019-094

  • News in Brief
    Enfortumab Vedotin Checks Urothelial Cancer
    Cancer Discov October 1 2019 9 (10) OF1-OF1; DOI:10.1158/2159-8290.CD-NB2019-104

  • News in Brief
    Entrectinib OK'd for Cancers with NTRK Fusions, NSCLC
    Cancer Discov October 1 2019 9 (10) OF2-OF2; DOI:10.1158/2159-8290.CD-NB2019-101

  • News in Brief
    Targeting WEE1 in Pancreatic Cancer
    Cancer Discov October 1 2019 9 (10) OF3-OF3; DOI:10.1158/2159-8290.CD-NB2019-103

  • News in Brief
    Neoadjuvant Pembrolizumab Takes on TNBC
    Cancer Discov October 1 2019 9 (10) OF4-OF4; DOI:10.1158/2159-8290.CD-NB2019-097

News in Depth

  • News in Depth
    TMB Faces Validation Hurdles
    Cancer Discov October 1 2019 9 (10) 1334-1334; DOI:10.1158/2159-8290.CD-ND2019-010

  • News in Depth
    RNA Technologies Expand Tool Kit for Cancer Immunotherapy
    Cancer Discov October 1 2019 9 (10) OF5-OF5; DOI:10.1158/2159-8290.CD-ND2019-009

Research Watch

  • Breast Cancer

    • Research Watch
      At Phase Ib, T-DM1 plus Neratinib Is Safe and Effective in Breast Cancer
      Cancer Discov October 1 2019 9 (10) 1339-1339; DOI:10.1158/2159-8290.CD-RW2019-137

  • Clinical Trials

    • Research Watch
      Safety and Preliminary Evidence of Efficacy Shown for Rogaratinib
      Cancer Discov October 1 2019 9 (10) 1337-1337; DOI:10.1158/2159-8290.CD-RW2019-131

    • Research Watch
      Adoptive Transfer of HPV-Targeted T Cells Is Active in Epithelial Cancer
      Cancer Discov October 1 2019 9 (10) OF6-OF6; DOI:10.1158/2159-8290.CD-RW2019-132

  • Drug Discovery

    • Research Watch
      The Structure of CCR7 Reveals a Binding Pocket for Antagonists
      Cancer Discov October 1 2019 9 (10) 1338-1338; DOI:10.1158/2159-8290.CD-RW2019-135

  • Drug Resistance

    • Research Watch
      Off-Target Alterations Drive Resistance to TRK Inhibitors in Some Cancers
      Cancer Discov October 1 2019 9 (10) OF7-OF7; DOI:10.1158/2159-8290.CD-RW2019-133

  • Glycation

    • Research Watch
      Deglycation of NRF2 by FN3K Promotes Oncogenesis and Drug Resistance
      Cancer Discov October 1 2019 9 (10) OF8-OF8; DOI:10.1158/2159-8290.CD-RW2019-125

  • Immunotherapy

    • Research Watch
      CRISPR Screening in T Cells Identifies Potential Immunotherapy Targets
      Cancer Discov October 1 2019 9 (10) OF9-OF9; DOI:10.1158/2159-8290.CD-RW2019-136

  • Leukemia

    • Research Watch
      Splicing Factor-Mutant Leukemias Are Sensitive to PRMT Inhibitors
      Cancer Discov October 1 2019 9 (10) 1336-1336; DOI:10.1158/2159-8290.CD-RW2019-129

  • Lymphoma

    • Research Watch
      High LMO2 Expression Confers Sensitivity to PARP Inhibition in DLBCL
      Cancer Discov October 1 2019 9 (10) 1337-1337; DOI:10.1158/2159-8290.CD-RW2019-134

  • Medulloblastoma

    • Research Watch
      OLIG2-Expressing Progenitors May Initiate Medulloblastoma Tumor Formation
      Cancer Discov October 1 2019 9 (10) 1338-1338; DOI:10.1158/2159-8290.CD-RW2019-140

  • Microbiome

    • Research Watch
      Tumor Microbiome Composition Influences Pancreatic Cancer Survival
      Cancer Discov October 1 2019 9 (10) 1335-1335; DOI:10.1158/2159-8290.CD-RW2019-128

  • Neuroblastoma

    • Research Watch
      Resistance to ALK Inhibitors in Neuroblastoma Is Regulated by BORIS
      Cancer Discov October 1 2019 9 (10) 1335-1335; DOI:10.1158/2159-8290.CD-RW2019-127

  • Pancreatic Cancer

    • Research Watch
      A Previously Unknown Mutation in RABL3 Is Linked to Hereditary PDAC
      Cancer Discov October 1 2019 9 (10) OF10-OF10; DOI:10.1158/2159-8290.CD-RW2019-130

  • Splicing

    • Research Watch
      Cancer-Linked SF3B1 Mutations Cause Faulty Splicing and SUGP1 Binding
      Cancer Discov October 1 2019 9 (10) 1336-1336; DOI:10.1158/2159-8290.CD-RW2019-138

  • Telomeres

    • Research Watch
      RAD51AP1 Promotes Maintenance of Telomere Length in ALT+ Cancer Cells
      Cancer Discov October 1 2019 9 (10) 1339-1339; DOI:10.1158/2159-8290.CD-RW2019-126

Back to top
PreviousNext
Cancer Discovery: 9 (10)
October 2019
Volume 9, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • In This Issue
  • In the Spotlight
  • Mini Review
  • Research Brief
  • Research Articles
  • News in Brief
  • News in Depth
  • Research Watch
    • Breast Cancer
    • Clinical Trials
    • Drug Discovery
    • Drug Resistance
    • Glycation
    • Immunotherapy
    • Leukemia
    • Lymphoma
    • Medulloblastoma
    • Microbiome
    • Neuroblastoma
    • Pancreatic Cancer
    • Splicing
    • Telomeres
Advertisement
  • Most Cited
  • Most Read
Loading
  • The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
  • Macrophages Regulate Response to Chemotherapy
  • Core Resistance Mechanisms and Genetic Evolution of Melanoma under BRAF Inhibitor Selection
  • EGFR Mediates RAF Inhibitor Resistance in BRAF-Mutant Colorectal Cancer
  • Novel Mutant-Selective EGFR Inhibitor Overcomes Drug Resistance
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement